LP17 (menselijk)

LP17 (human) is a TREM1 antagonist peptide with anti-inflammatory and anti-cancer effects[1].

887973-05-9

12352209

TREM receptor

Immunology/Inflammation

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

90.14

O=C(N1[C@@H](CCC1)C(O)=O)[C@H]2N(CCC2)C([C@H](CCC(N)=O)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H](C(C)C)NC([C@H](CS)NC([C@H](CCC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC(CNC([C@H](CO)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O

C88H134N20O28S

1952.19

[1]Roh SA, et al. SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability. Anticancer Res. 2021 Nov;41 (11) :5431-5444.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10938/LP17-human-SDS-MedChemExpress.pdf

Peptides

No Development Reported